WO200153312 Comparison

ID AAM39781 standard; Protein; 772 AA.
XX
AC AAM39781;
XX
DT 22-OCT-2001 (first entry)
XX
DE Human polypeptide SEQ ID NO 2926.
XX
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia.
XX
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US34263.
XX
PR 21-JAN-2000; 2000US-0488725.
PR 25-APR-2000; 2000US-0552317.
PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000; 2000US-0653450.
PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
XX
DR WPI; 2001-442253/47.
DR N-PSDB; AAI58937.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -
XX
PS Example 4; SEQ ID NO 2926; 10078pp; English.
XX
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic

CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.
XX
SQ Sequence 772 AA;

Query Match 100.0%; Score 4037; DB 22; Length 772;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 772; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 MRLSSLLALLRPALPLILGLSLGCSLSLLRVSWIQGEGEDPCVEAVGERGGPQNPDSRAR 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 mrlssllallrpalplilglslgcslsllrvswiqgegedpcveavgerggpqnpdsrar 60

Qy      61 LDQSDEDFKPRIVPYYRDPNKPYKKVLRTRYIQTELGSRERLLVAVLTSRATLSTLAVAV 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 ldqsdedfkprivpyyrdpnkpykkvlrtryiqtelgsrerllvavltsratlstlavav 120

Qy     121 NRTVAHHFPRLLYFTGQRGARAPAGMQVVSHGDERPAWLMSETLRHLHTHFGADYDWFFI 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 nrtvahhfprllyftgqrgarapagmqvvshgderpawlmsetlrhlhthfgadydwffi 180

Qy     181 MQDDTYVQAPRLAALAGHLSINQDLYLGRAEEFIGAGEQARYCHGGFGYLLSRSLLLRLR 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 mqddtyvqaprlaalaghlsinqdlylgraeefigageqarychggfgyllsrslllrlr 240

Qy     241 PHLDGCRGDILSARPDEWLGRCLIDSLGVGCVSQHQGQQYRSFELAKNRDPEKEGSSAFL 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     241 phldgcrgdilsarpdewlgrclidslgvgcvsqhqgqqyrsfelaknrdpekegssafl 300

Qy     301 SAFAVHPVSEGTLMYRLHKRFSALELERAYSEIEQLQAQIRNLTVLTPEGEAGLSWPVGL 360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     301 safavhpvsegtlmyrlhkrfsaleleraYseieqlqaqirnltvltpegeaglswpvgl 360

Qy     361 PAPFTPHSRFEVLGWDYFTEQHTFSCADGAPKCPLQGASRADVGDALETALEQLNRRYQP 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     361 papftphsrfevlgwdyfteqhtfscadgapkcplqgasradvgdaletaleqlnrryqp 420

Qy     421 RLRFQKQRLLNGYRRFDPARGMEYTLDLLLECVTQRGHRRALARRVSLLRPLSRVEILPM 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     421 rlrfqkqrllngyrrfdpargmeytldlllecvtqrghrralarrvsllrplsrveilpm 480

Qy     481 PYVTEATRVQLVLPLLVAEAAAAPAFLEAFAANVLEPREHALLTLLLVYGPREGGRGAPD 540
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     481 pyvteatrvqlvlpllvaeaaaapafleafaanvleprehalltlllvygpreggrgapd 540

Qy     541 PFLGVKAAAAELERRYPGTRLAWLAVRAEAPSQVRLMDVVSKKHPVDTLFFLTTVWTRPG 600
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     541 pflgvkaaaaelerrypgtrlawlavraeapsqvrlmdvvskkhpvdtlffllttvwtrpg 600

Qy     601 PEVLNRCRMNAISGWQAFFPVHFQEFNPALSPQRSPPGPPGAGPDPPSPPGADPSRGAPI 660
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     601 pevlnrcrmnaisgwqaffpvhfqefnpalspqrsppgppgagpdppsppgadpsrgapi 660
```

```
Qy     661 GGRFDRQASAEGCFYNADYLAARARLAGELAGQEEEEALEGLEVMDVFLRFSGLHLFRAV 720
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     661 ggrfdrqasaegcfynadylaararlagelagqeeeealeglevmdvflrfsglhlfrav 720

Qy     721 EPGLVQKFSLRDCSPRLSEELYHRCRLSNLEGLGGRAQLAMALFEQEQANST 772
           ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     721 epglvqkfslrdcsprlseelyhrcrlsnleglggraqlamalfeqeqanst 772


RESULT   2
AAB80269
ID   AAB80269 standard; Protein; 772 AA.
XX
AC   AAB80269;
XX
DT   24-APR-2001  (first entry)
XX
DE   Human PRO339 protein.
XX
KW   Human; PRO; dermatological; antipsoriatic; cytostatic; antiinflammatory;
KW   antiparkinsonian nootropic; neuroprotective; vulnerary; cardiant;
KW   antiangiogenic; vasotropic; antiasthmatic; antirheumatic; cancer;
KW   antiarthritic; antiinfertility; antidiabetic; antiviral; diabetes;
KW   ophthalmological; gene therapy; skin disease; gastrointestinal disorder;
KW   ischaemia; inflammation.
XX
OS   Homo sapiens.
XX
PN   WO200104311-A1.
XX
PD   18-JAN-2001.
XX
PF   22-FEB-2000; 2000WO-US04414.
XX
PR   07-JUL-1999;   99US-0143048.
PR   26-JUL-1999;   99US-0145698.
PR   28-JUL-1999;   99US-0146222.
PR   08-SEP-1999;   99WO-US20594.
PR   13-SEP-1999;   99WO-US20944.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   05-OCT-1999;   99WO-US23089.
PR   29-NOV-1999;   99WO-US28214.
PR   30-NOV-1999;   99WO-US28313.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   20-DEC-1999;   99WO-US30999.
PR   05-JAN-2000;   99WO-US00219.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Botstein D,  Desnoyers L,  Eaton DL,  Ferrara N;
PI   Filvaroff E,  Fong S,  Gao W,  Gerber H,  Gerritsen ME,  Goddard A;
PI   Godowski PJ,  Grimaldi CJ,  Gurney AL,  Hillan KJ,  Kljavin IJ;
PI   Mather JP,  Pan J,  Paoni NF,  Roy MA,  Stewart TA,  Tumas D;
PI   Williams PM,  Wood WI;
XX
```

ID AAI58937 standard; cDNA; 2710 BP.
AC AAI58937;
DT 22-OCT-2001 (first entry)
DE Human polynucleotide SEQ ID NO 1140.
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia; ss.
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US34263.
XX
PR 21-JAN-2000; 2000US-0488725.
PR 25-APR-2000; 2000US-0552317.
PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000; 2000US-0653450.
PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
XX
DR WPI; 2001-442253/47.
DR P-PSDB; AAM39781.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -
XX
PS Claim 1; SEQ ID NO 1140; 10078pp; English.
XX
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.
XX
SQ Sequence 2710 BP; 506 A; 821 C; 824 G; 559 T; 0 other;

Query Match 96.5%; Score 2692; DB 22; Length 2710;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2692; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 98 gggggttagttccgacaccttcacagttgaagagcaggcagaaggagttgtgaagacagg 157




Qy 1118 cctcattgactctctgggcgtcggctgtgtctcacagcaccaggggcagcagtatcgctc 1177
Db 1027 cctcattgactctctgggcgtcggctgtgtctcacagcaccaggggcagcagtatcgctc 1086
Qy 1178 atttgaactggccaaaaatagggaccctgagaaggaagggagctcggctttcctgagtgc 1237
Db 1087 atttgaactggccaaaaatagggaccctgagaaggaagggagctcggctttcctgagtgc 1146
Qy 1238 cttcgccgtgcaccctgtctccgaaggtaccctcatgtaccggctccacaaacgcttcag 1297
Db 1147 cttcgccgtgcaccctgtctccgaaggtaccctcatgtaccggctccacaaacgcttcag 1206
Qy 1298 cgctctggagttggagcgggcttacagtgaaatagaacaactgcaggctcagatccggaa 1357
Db 1207 cgctctggagttggagcgggcttacagtgaaatagaacaactgcaggctcagatccggaa 1266
Qy 1358 cctgaccgtgctgacccccgaaggggaggcagggctgagctggcccgttgggctccctgc 1417
Db 1267 cctgaccgtgctgacccccgaaggggaggcagggctgagctggcccgttgggctccctgc 1326
Qy 1418 tcctttcacaccacactctcgctttgaggtgctgggctgggactacttcacagagcagca 1477
Db 1327 tcctttcacaccacactctcgctttgaggtgctgggctgggactacttcacagagcagca 1386
Qy 1478 caccttctcctgtgcagatggggctcccaagtgcccactacaggggctagcagggcgga 1537
Db 1387 caccttctcctgtgcagatggggctcccaagtgcccactacaggggctagcagggcgga 1446
Qy 1538 cgtgggtgatgcgttggagactgccctggagcagctcaatcggcgctatcagccccgcct 1597
Db 1447 cgtgggtgatgcgttggagactgccctggagcagctcaatcggcgctatcagccccgcct 1506
Qy 1598 gcgcttccagaagcagcgactgctcaacggctatcggcgcttcgacccagcacggggcat 1657
Db 1507 gcgcttccagaagcagcgactgctcaacggctatcggcgcttcgacccagcacggggcat 1566
Qy 1658 ggagtacaccctggacctgctgttggaatgtgtgacacagcgtgggcaccggcgggccct 1717
Db 1567 ggagtacaccctggacctgctgttggaatgtgtgacacagcgtgggcaccggcgggccct 1626
Qy 1718 ggctcgcagggtcagcctgctgcggccactgagccgggtggaaatcctacctatgcccta 1777
Db 1627 ggctcgcagggtcagcctgctgcggccactgagccgggtggaaatcctacctatgcccta 1686
Qy 1778 tgtcactgaggccacccgagtgcagctggtgctgccactcctggtggctgaagctgctgc 1837
Db 1687 tgtcactgaggccacccgagtgcagctggtgctgccactcctggtggctgaagctgctgc 1746
Qy 1838 agccccggctttcctcgaggcgtttgcagccaatgtcctggagccacgagaacatgcatt 1897
Db 1747 agccccggctttcctcgaggcgtttgcagccaatgtcctggagccacgagaacatgcatt 1806
Qy 1898 gctcaccctgttgctggtctacgggccacgagaaggtggccgtggagctccagacccatt 1957
Db 1807 gctcaccctgttgctggtctacgggccacgagaaggtggccgtggagctccagacccatt 1866
Qy 1958 tcttggggtgaaggctgcagcagcggagttagagcgacggtaccctgggacgaggctggc 2017
Db 1867 tcttggggtgaaggctgcagcagcggagttagagcgacggtaccctgggacgaggctggc 1926
Qy 2018 ctggctcgctgtgcgagcagaggcccctcccaggtgcgactcatggacgtggtctcgaa 2077
Db 1927 ctggctcgctgtgcgagcagaggcccctcccaggtgcgactcatggacgtggtctcgaa 1986
Qy 2078 gaagcaccctgtggacactctcttcttccttaccaccgtgtggacaaggcctgggcccga 2137